ANDA 76271, held by Sandoz. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 76271 (Ketorolac Tromethamine), held by Sandoz, was first approved by FDA on Oct 6, 2004, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2004 | Original application | Approved | None posted |
| Ketorolac Tromethamine15MG/ML · injectable;injection | Ketorolac Tromethamine | Discontinued |
| Ketorolac Tromethamine30MG/ML · injectable;injection | Ketorolac Tromethamine | Rx |
| Nov 21, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 11, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 11, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 28, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 15, 2012 | Supplement 3Labeling | Approved | None posted |
| Oct 6, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters